New Horizons in the Treatment of Early Stage NSCLC

Post-meeting Survey

Please select your speciality: *

Oncologist
Pulmonologist
Surgeon

Based on the meeting today and your clinical experience, for which PD-L1 expression levels would you consider using neoadjuvant immunotherapy. (Please select all that apply) *

<1%
1–49%
≥50%
Other

Based on the meeting today and your clinical experience, for which PD-L1 expression levels would you consider using adjuvant immunotherapy. (Please select all that apply) *

<1%
1–49%
≥50%
Other

Would you consider using periadjuvant therapy for patients with NSCLC? *

Please rank the following treatments that you consider would be most beneficial for patients with resectable NSCLC without driver mutations? Disregard cost considerations. (With 1 being most beneficial and 7 being the least beneficial. Please do not repeat the same number for different options.)

a. Neoadjuvant immunotherapy *

b. Adjuvant immunotherapy *

c. Periadjuvant immunotherapy *

d. Resection only *

e. Neoadjuvant chemotherapy *

f. Adjuvant chemotherapy *

g. Concurrent chemoradiotherapy + immunotherapy *

Please rate the talk by Professor Yi Long Wu *

Very satisfied	Satisfied	Neutral	Dissatisfied	Very dissatisfied
Very satisfiedItem #1 Very satisfied	SatisfiedItem #1 Satisfied	NeutralItem #1 Neutral	DissatisfiedItem #1 Dissatisfied	Very dissatisfiedItem #1 Very dissatisfied

Please rate the talk by Professor Rina Hui *

Very satisfied	Satisfied	Neutral	Dissatisfied	Very dissatisfied
Very satisfiedItem #1 Very satisfied	SatisfiedItem #1 Satisfied	NeutralItem #1 Neutral	DissatisfiedItem #1 Dissatisfied	Very dissatisfiedItem #1 Very dissatisfied

Please rate the panel discussion *

Very satisfied	Satisfied	Neutral	Dissatisfied	Very dissatisfied
Very satisfiedItem #1 Very satisfied	SatisfiedItem #1 Satisfied	NeutralItem #1 Neutral	DissatisfiedItem #1 Dissatisfied	Very dissatisfiedItem #1 Very dissatisfied

Please rate the overall preparation and delivery of the meeting *

Very satisfied	Satisfied	Neutral	Dissatisfied	Very dissatisfied
Very satisfiedItem #1 Very satisfied	SatisfiedItem #1 Satisfied	NeutralItem #1 Neutral	DissatisfiedItem #1 Dissatisfied	Very dissatisfiedItem #1 Very dissatisfied

Please share any further comments that would help us to improve our future events.

HK-9377 08/2023